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Background: The implications of two-stage revision on mental health are poorly understood. The purpose of this study is to determine (1) whether patients undergoing two-stage revision total hip and knee
arthroplasty for prosthetic joint infection were more likely to get Patient-Reported Outcomes Measurement Information System (PROMIS) Depression scores consistent with major depressive disorder
(MDD) than those undergoing aseptic revision and (2) whether these symptoms resolved after the
procedure.
Methods: Records of all 366 patients that underwent revision total hip or knee arthroplasty from January
1, 2015, e June 20, 2019, were reviewed. Forty-two patients were excluded for missing PROMIS
Depression scores or incomplete treatment. Preoperative (<3 months), early postoperative (2-8 weeks),
and ﬁnal postoperative (6-18 months) Depression scores were collected. Patients crossing the PROMIS
Depression threshold equivalent to a Patient Health Questionnaire-9 score 10, indicative of MDD, were
evaluated.
Results: More two-stage revision patients developed Depression scores indicative of MDD perioperatively than the aseptic cohort (20.0% vs 6.5%, P ¼ .01). Two-stage revision patients had higher (worse)
median Depression scores preoperatively (54.8 vs 51.3, P ¼ .04) and at early follow-up (54.3 vs 49.9,
P ¼ .01), but not at ﬁnal follow-up (50.4 vs 49.1, P ¼ .39). Across all patients, Depression scores improved
by 2.4 points at early follow-up (95% conﬁdence interval:1.1e3.7; P < .001) and 3 points at ﬁnal follow-up
(95% conﬁdence interval:1.5-4.5; P < .001; minimal clinically important difference 3.0).
Conclusions: Twenty percent of two-stage revision arthroplasty patients, compared to <7% of aseptic
revision patients, developed PROMIS Depression scores consistent with MDD during treatment. At ﬁnal
follow-up, a clinically signiﬁcant improvement in Depression scores from baseline was evident in both
cohorts.
© 2021 The Authors. Published by Elsevier Inc. on behalf of The American Association of Hip and Knee
Surgeons. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Prosthetic joint infection (PJI) is a major complication after total
joint arthroplasty (TJA), with a reported prevalence of up to 2.5% in
total hip arthroplasty and 2% in total knee arthroplasty in standard
US populations [1,2]. Two-stage revision, currently the most
commonly performed treatment for PJI in the United States, carries
substantial morbidity [2-5]. The process involves an initial revision
surgery to remove infected hardware and place an antibiotic-laden
cement spacer followed by a minimum of 6 weeks of IV antibiotics,
often while remaining non-weight-bearing and immobilized. The
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two-stage revision is then completed with a second surgery to
remove the antibiotic spacer and replace the prosthesis, often after
an antibiotic holiday that adds additional time for the patient
before reimplantation. Medical complications, hospitalization time,
patient mobility, and cost have been compared between one- and
two-stage revisions; however, the mental health implications of
these treatments have not been studied [3,4].
Depressed patients undergoing primary or revision TJA have
been shown to have worse outcomes, including more pain, poorer
functional status, and increased rates of readmission and infection
[6-10]. In addition, pharmacologic treatment of depression is
associated with greater improvements in physical function postoperatively in primary TJA patients [11]. Therefore, understanding
the mental health risks of patients undergoing revision TJA is a
critical component of their management.
The Patient Health Questionnaire-9 (PHQ-9) is a well-validated
tool that is widely used in a variety of medical settings to screen,
diagnose, and monitor treatment of major depressive disorder
(MDD) [12-14]. Using a score cutoff of 10, indicating “moderate
depression,” maximizes the PHQ-9’s sensitivity and speciﬁcity for
diagnosis of MDD [14,15]. While the PHQ-9 is both effective and
reliable, there has been considerable interest in reducing the
number of questions presented to patients for ease and speed of
screening [16,17].
Utilization of computer adaptive testing, including the NIHdeveloped Patient-Reported Outcomes Measurement Information
System (PROMIS), has allowed for simpler patient screening while
maintaining high precision and reliability [18-20]. Depressive
symptoms can be assessed by PROMIS. Because PROMIS Depression
scores have been deﬁned in relation to PHQ-9, they can be easily
converted to PHQ-9 scores [21]. This is most clinically relevant for
PROMIS Depression scores of 59.9, which is equivalent to a PHQ-9
score of 10, and can be used to support a diagnosis of MDD [21,22].
Our goal in this study was to determine (1) whether patients undergoing two-stage revision for PJI are more likely to develop
PROMIS Depression scores consistent with MDD in the perioperative period than those undergoing aseptic revision and (2) whether
these symptoms resolved after surgery.
Material and methods
After IRB approval, an a priori power analysis was performed
and identiﬁed that 300 patients would be required to detect clinically relevant differences in PROMIS Depression scores between
aseptic and two-stage revision cohorts at our enrollment ratio of
1.88 to 1. Differences in PROMIS Depression scores of 3 points have
been established as the minimal clinically important difference
(MCID) in multiple noncancer patient populations [18,23].
A retrospective review was performed by querying a database of
24 attending orthopedic surgeons and fellows practicing at two
hospitals within a single academic institution. All patients older
than 18 years who underwent revision of THA or TKA from January
1, 2015, through June 20, 2019, were initially included. This produced a list of 366 patients, of which 15 were excluded from the
study for missing PROMIS scores. Among those who began twostage revision treatment for PJI, 12 were excluded for undergoing
amputation, 8 were excluded for undergoing knee fusion, and 9
were excluded for otherwise not completing the second (replant)
stage of the revision. During the study period, no patients at our
institution were treated for PJI with one-stage revision arthroplasty
or debridement, antibiotics, and implant retention. The ﬁnal study
population included 210 patients that underwent one-stage revision for aseptic failure as determined by Musculoskeletal Infection
Society criteria and 112 patients that underwent a completed twostage revision for PJI. Two of the 112 two-stage revision patients
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had undergone prior failed liner exchange, and three had undergone prior failed two-stage revision.
Medical records were reviewed to identify patient age, sex,
height, weight, body mass index (BMI), American Society of Anesthesiologists (ASA) score, prior diagnosis of depression documented in past medical history, prior diagnosis of anxiety, or active
prescription of antidepressants. PROMIS depression scores were
collected at four perioperative time points for those who underwent two-stage revision for PJI: less than 3 months before explant,
less than 1 month before replant, 2-8 weeks after replant (early
follow-up), and 6-18 months after replant (ﬁnal follow-up). For
those who underwent one-stage revision, PROMIS depression
scores were collected at three time points: less than 3 months
before revision, 2-8 weeks after revision (early follow-up), and 6-18
months after revision (ﬁnal follow-up). Scores that were obtained
outside of these perioperative periods were discarded. The proportion of patients with PROMIS Depression scores 59.9 at each
time point was noted, as this corresponds to a score 10 on the
PHQ-9 and thus has high sensitivity and speciﬁcity for diagnosis of
MDD [15,21]. Weight-bearing status in the time between explant
and replant surgeries was also recorded in the two-stage revision
cohort.
Comparisons of demographic information and PROMIS scores
between the two-stage and aseptic revision cohorts were conducted via Kruskal-Wallis and Pearson's chi-square testing (Figs. 1
and 2). No categorical comparisons had small enough cohorts to
require the use of Fisher’s exact testing. A repeated measures mixed
model was used to determine the overall effect of demographic
variables and time since the ﬁnal surgery on PROMIS Depression
scores.
Results
A total of 322 patients, including 189 females and 133 males,
were included in the study (Table 1). The median age at time of
revision was 66 years (range 19 - 93 years), and the median BMI
was 30.5 (range 15.7 - 61.55). Seventy-seven percent (112 of 145) of
patients who began two-stage revision treatment for PJI underwent
replant and were thus eligible to be included in the analysis. The
median time between explant and replant in the two-stage revision
cohort was 15.9 weeks (range 0.6 - 82.3 weeks; interquartile range
12.3 e 20.4 weeks). Of the 112 patients who completed two-stage
revision treatment, there was no known recurrence of infection
at ﬁnal follow-up clinic visit in 102 cases (91%). Eighty-two percent
(92 of 112) of the two-stage revision cohort had a static antibiotic
spacer placed and were non-weight-bearing in the time between
explant and replant surgeries. The remaining 18% (20 of 112) of the
two-stage revision cohort had an articulating spacer placed and
could bear weight between explant and replant surgeries.
Compared to the one-stage revision cohort, patients undergoing
two-stage revision for PJI had higher BMI (29.8 vs 31.6, P ¼ .006),
had higher ASA (2.8 vs 2.6; P ¼ .013), and had been diagnosed with
anxiety (48% vs 15%; P < .001) and depression at a higher rate (64%
vs 18%; P < .001). All other demographic information was similar
between the two cohorts (Table 1).
Ten of 50 patients (20%) with preoperative Depression scores
<59.9 undergoing two-stage revision developed Depression scores
indicative of new-onset or re-emergent MDD perioperatively
(Fig. 2). Eight of 124 patients (6.4%) with preoperative Depression
scores <59.9 undergoing aseptic revision developed new-onset or
re-emergent scores indicative of MDD (Fig. 2, P ¼ .013). Patients
undergoing two-stage revision for PJI had signiﬁcantly higher
(worse) median PROMIS Depression scores than those undergoing
aseptic revision preoperatively (54.8 vs 51.4, P ¼ .04) and at early
follow-up (54.3 vs 49.9, P ¼ .01; Fig. 1). No signiﬁcant difference in
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Figure 1. Median perioperative PROMIS Depression scores in context of the PHQ-9. Red lines represent Depression scores equivalent to cutoff values for the PHQ-9 categories.
Median PROMIS Depression scores were signiﬁcantly higher in the two-stage revision cohort before revision/explant and at early follow-up. No differences between cohorts
remained at the ﬁnal follow-up. Median Depression scores for both cohorts failed to reach the PHQ-9 threshold for moderate depression. PHQ-9 scores indicative of moderate
depression have the highest sensitivity and speciﬁcity in diagnosis of major depressive disorder [15].

Depression was observed between the two cohorts at the ﬁnal
follow-up (50.4 vs 49.1, P ¼ .39; Fig. 1). Within the 2-stage revision
cohort, no difference in median Depression scores was noted between patients with articulating vs nonarticulating antibiotic
spacers at any time point (P > .05 for all). The overall rates of MDDrange scores in each cohort, regardless of preoperative Depression
scores, are listed in Table 2.

On multivariate analysis, previously diagnosed depression was
found to be an independent predictor of higher (worse) PROMIS
Depression scores (D3.4; 95% CI 0.5e6.3; P ¼ .02). Active antidepressant prescription before surgery was another independent
predictor of higher Depression scores (D5.4, P < .001). Despite
signiﬁcant ﬁndings on a univariate analysis, revision for PJI was not
an independent predictor of worse PROMIS scores on multivariate

Figure 2. Development of PROMIS Scores indicative of new-onset or re-emergent major depressive disorder (MDD). Patients with preoperative Depression scores below the PHQ-9
cutoff for moderate depression were included in this analysis. Twelve percent of the two-stage revision cohort developed Depression scores indicative of MDD before replant. An
additional 6% crossed the MDD threshold by early follow-up and 2% more did by the ﬁnal follow-up, for a total of 20% of the cohort (10/50). By early follow-up, 4.8% of the aseptic
revision cohort had developed Depression scores indicating MDD, and an additional 1.6% had done so by the ﬁnal follow-up, for a total of 6.4% of the cohort (8/116). PHQ-9 scores
indicative of moderate depression have the highest sensitivity and speciﬁcity in diagnosis of major depressive disorder [15].
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Table 1
Demographic comparisons of two-stage vs aseptic revision cohorts.
Factor

Total (N ¼ 322)

Aseptic revision (N ¼ 210)

Two-stage revision (N ¼ 112)

Age (y)
BMI
ASA
Sex
Male
Female
PMH depression
No
Yes
PMH anxiety
No
Yes
Antidepressant
No
Yes

66.0 [60-73]
30.5 [26-36]
2.61 [2-3]

67.0 [60-75]
29.8 [26-34]
2.56 [2-3]

65.0 [60-72]
31.6 [27-39]
2.76 [2-3]

189 (59%)
133 (41%)

122 (58%)
88 (42%)

67 (60%)
45 (40%)

212 (66%)
110 (34%)

172 (82%)
38 (18%)

40 (36%)
72 (64%)

235 (73%)
85 (27%)

178 (85%)
32 (15%)

57 (52%)
53 (48%)

158 (49%)
162 (51%)

106 (51%)
104 (49%)

52 (47%)
58 (53%)

P value
0.085a
0.006a
0.013a
0.76b

<0.001b

<0.001b

0.59b

PMH depression, anxiety, diagnosis available in patient’s medical record at the time of preoperative clinic visit.
Data not available for all subjects. Missing values: BMI ¼ 1, ASA ¼ 40, PMH anxiety ¼ 2, antidepressant ¼ 2.
Bolded values indicate statistical signiﬁcance.
a
ANOVA.
b
Kruskal-Wallis test.

analysis (P > .05). Time since ﬁnal surgery was identiﬁed as an
independent predictor of lowered (better) Depression scores
compared with preoperative baseline: this effect did not meet
MCID by early follow-up (D2.5; 95% CI: 1.1e3.7; P < .001) but did
meet MCID by the ﬁnal follow-up (D3.0; 95% CI: 1.5e4.5; P < .001).
Discussion
Compared with the aseptic revision cohort, a greater proportion
of patients undergoing two-stage revision developed PROMIS
scores indicative of new-onset or re-emerged MDD. PROMIS
Depression scores were increased preoperatively in patients
undergoing two-stage compared with aseptic revision, but this
difference resolved by the ﬁnal postoperative follow-up. Preexisting depression and active antidepressant use were found to
independently predict worsened PROMIS scores throughout the
perioperative period for all patients. Finally, Depression scores
improved from preoperative baseline by early follow-up, although
not reaching the MCID. This improvement reached the MCID by the
ﬁnal follow-up.
There are multiple possible reasons for the observed differences
in PROMIS Depression scores between cohorts in this study. The
high morbidity of two-stage revision as a potential etiology of
depression has been documented. Caroll et al. (2020) found that
patients who underwent either one- or two-stage revision
arthroplasty for PJI strongly preferred having only one operation
and minimizing the time from start of treatment to resumption of
normal activities [24]. Notably, preoperative PROMIS scores in this
study were generally obtained before any discussion of surgical
treatment, so the elevated preoperative Depression scores in our PJI
patients are likely not related to anticipation of the length and
morbidity of a two-stage revision. Preoperatively, the presence of
PJI itself, with its associated pain and dysfunction, may contribute
more to preoperative depression than the morbidity of the twostage revision [25]. Later in the perioperative period (before
explant, early follow-up), elevated Depression scores may be due to
a combination of two-stage revision morbidity and residual
symptoms from PJI [24,25].
Our study also found that active antidepressant use before
surgery was associated with worsened perioperative Depression
scores in our patient population. This cohort likely had severe preexisting MDD exacerbated by the course of surgical treatment.
Conversely, greater time since ﬁnal operation was found to be an

independent predictor of lower (better) PROMIS Depression scores.
This suggests that even those patients who require antidepressant
therapy in the two-stage revision perioperative period experience
improvement as they recover. Thus, patients with MDD undergoing
TJA revision may beneﬁt from frequent re-evaluation of depressive
symptoms and discontinuation of pharmacologic antidepressants
when indicated.
Prior studies have shown that depressed TJA patients have
worse functional outcomes, as well as increased pain, rates of
readmission, and PJI [6-10]. Causality has not been established, so it
is possible that depression contributes to worse pain/function, that
worse pain/function contribute to depression, or a combination of
both [6-10]. Mental health issues can become obstacles to participation in rehabilitation, appropriate nutrition and self-care, and
ability to comply with follow-up and treatment for orthopedic as
well as other medical conditions; any of these could potentially
contribute to the aforementioned issues [26-29]. As such, recognizing and treating clinical depression could represent an opportunity to optimize patient outcomes.
The PHQ-9 has been identiﬁed as a valuable tool in all aspects of
MDD treatment, including screening, treatment recommendations,
and measurement of treatment response [30,31]. Because PROMIS
Depression scoring in relation to the PHQ-9 has been deﬁned, the
potential beneﬁts of PHQ-9 scoring in the TJA population can be
Table 2
Overall rates of PROMIS scores indicative of moderate depression.
Perioperative
time point
Before explant/revision
No/mild depression
Moderate depression
Before replant
No/mild depression
Moderate depression
Early follow-up
No/mild depression
Moderate depression
Final follow-up
No/mild depression
Moderate depression

Total

Aseptic
revision

Two-stage
revision

174 (77%)
51 (23%)

124 (81%)
29 (19%)

50 (69%)
22 (31%)

NA
NA

50 (66%)
26 (34%)

246 (73%)
53 (27%)

162 (85%)
28 (15%)

84 (77%)
25 (23%)

164 (83%)
33 (17%)

110 (87%)
17 (13%)

54 (77%)
16 (23%)

P value
.13

NA
50 (66%)
26 (34%)

.14

.16

Values presented as N (column %). P values calculated via Pearson's chi-square test.
Data not available for all subjects. Missing values: before explant/revision ¼ 97,
before replant ¼ 36, early follow-up ¼ 23, ﬁnal follow-up ¼ 125. All patients were
included in this analysis regardless of preoperative Depression score.
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obtained more quickly via computer adaptive PROMIS testing [32].
The proportions of patients of both study cohorts with PROMIS
Depression scores 59.9 are substantial (Fig. 2, Table 2). While
causality cannot be proven, certain patients may have improved
psychological and perioperative outcomes with initiation or increase of treatments, such as pharmacologic antidepressants and/
or cognitive behavioral therapy [6,9,11]. We, therefore, recommend
frequent screening for MDD and referral for antidepressant therapy
when indicated for patients undergoing revision arthroplasty.
Study limitations
This study is substantially limited by its retrospective design.
Depression scores were not available for all desired time points for
every patient. Although our data would suggest that two-stage revision patients who do not undergo reimplantation would have the
worst PROMIS Depression scores of all groups, the low rate of
Depression score availability in this subcohort precluded this analysis.
In addition, patients in the aseptic and two-stage revision cohorts
differed in several respects. On average, patients undergoing twostage revision had ASA scores 0.2 points higher, a difference that
was statistically but likely not clinically signiﬁcant (2.76 vs 2.56, P ¼
.013). More relevant, patients undergoing two-stage revision for PJI
had higher BMI (31.6 vs 29.8, P ¼ .006) and were more likely to have a
past medical history including depression than those undergoing
aseptic revision (64% vs 18%, P < .001). The association of elevated BMI
and depression has been well-documented in the literature as well
[33-35]. Our ﬁnding of elevated BMI in the two-stage revision cohort
is consistent with literature indicating that periprosthetic infection
risk increases with obesity [36-38]. The higher rates of pre-existing
depression observed in the two-stage revision cohort are also
consistent with studies indicating that depressed patients are at
increased risk of PJI [9,38]. Notably, we did not ﬁnd elevated BMI to be
an independent risk factor for worse Depression scores in our
regression analysis, potentially because other factors were correlated
with BMI and so absorbed some of its effect.
Because single-stage revision was not used as a treatment for PJI
at our institution during the study period, we did not have such a
cohort available for comparison. As such, we were unable to determine the extent to which differences in perioperative PROMIS scores
between the cohorts were related to the underlying condition (ie,
infection) or its treatment. We were likewise unable to distinguish
between the effects of speciﬁc treatment factors, including the
period of immobility, need for a second revision surgery, antibiotics,
or prolonged duration of treatment. A follow-up study comparing
patient-reported depression scores in those who underwent onestage vs two-stage revision for PJI would be needed to better characterize the etiology of the depressive symptoms we observed.
Antidepressant therapy regimens were not initiated or managed
as part of the present study. As such, further research is needed to
determine whether initiating or increasing treatment is effective in
patients who develop clinically signiﬁcant depression based on
perioperative PROMIS scores. Finally, our study was not designed to
capture the population of patients who did not complete a twostage revision procedure and may be at high risk for depression.
Conclusions
Approximately three times more patients undergoing two-stage
revision for PJI develop PROMIS Depression scores indicative of
new-onset or re-emergent MDD than those undergoing aseptic
revision. A pre-existing diagnosis of depression is an independent
predictor for clinically signiﬁcant worsening of PROMIS Depression
scores during revision arthroplasty and should be aggressively
managed. In all patients, time since ﬁnal operation is an

independent predictor of improved PROMIS Depression scores,
highlighting the substantial long-term beneﬁts of revision arthroplasty in appropriately selected populations.
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